ScinoPharm has received the Potent Compound Safety Certification from SafeBridge Consultants. The company claims that, with a cGMP manufacturing facility designed to manufacture cytotoxic and high potency compounds, ScinoPharm can handle a range of oncology and hormonal products, and other APIs made of small molecules, peptides and nucleic acids in its other production lines.
Additionally, the company has over 12 FDA approved, independent production lines with separate air handling systems. Some of the lines are reserved for non-cytotoxic (lower potency) compounds. Facilities not destined for handling high potency products were not part of the Certification program.
Jo Shen, president and CEO of ScinoPharm, said: “The Certification demonstrates our company’s commitment to maintaining international standards. Not only are our plants cGMP certified, our stringent enforcement of environmental, health and safety codes are rarities in Asia.”
ScinoPharm is the first API company in Asia to receive the certification alongwith six other facilities in the US and Europe involved in the SafeBridge Potent Compound Safety Certified program till date.